Porsolt is a long-established preclinical CRO, having started operations in 1984 under the name ITEM-Labo. Porsolt has obtained an international reputation for expertise in physiopathological models, customized procedures and tailored solutions for discovering treatments of psychiatric and neurological disorders, acute and chronic pain, inflammation, cardiac and vascular diseases, and metabolic and eating disorders. Porsolt also offers services for safety evaluation of drug candidates from screening to pre-Phase 1 regulatory studies (ICH S7), in full compliance with GLP. Porsolt’s safety program includes full assessment of arrhythmogenic risk and abuse/dependence liability. Porsolt is headquartered in France with research facilities in Laval. For additional information about the organization, please visit www.porsolt.com or email us at contact@porsolt.com